Glyko announces research grants:
This article was originally published in Clinica
Glyko Biomedical (US) has been awarded a $60,000 development grant for AZT resistance diagnostics. The award from the Paediatric AIDS Foundation will fund a test for AZT drug resistance in people with AIDS. Glyko also received a Phase I SBIR award worth $67,000 from the National Institutes of Health to expand indications for its lysosomal disease test. The company's urinary carbohydrate analysis test for lysosomal storage disease is currently pending US FDA clearance. Lysosomal storage disorders are among the most commonly inherited metabolic diseases and affect around 30,000 people in the US.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.